Citations
32
16.0 per year
Published
2023
Oral fluvoxamine with inhaled budesonide for treatment of early COVID-19 in the community: a randomised, double-blind, placebo-controlled, adaptive platform trial
The Lancet Respiratory Medicine•2023
Authors
G Reis, EASM Silva, DCM Silva, LJ Thabane, AC Ferreira, VEG de Souza-Campos, APM Almeida, AM Nogueira, EDS Callegari, ADF de Figueiredo-Neto, PS Menezes de Sá, KK Shinjo, JI Forrest, JH Park, CS Wiens, CM Guo, K Thorlund, EJ Mills
The Lancet
COVID-19
Fluvoxamine
Abstract
Background: Fluvoxamine and budesonide have shown promise as treatments for early COVID-19. We assessed the efficacy of oral fluvoxamine combined with inhaled budesonide versus placebo in preventing hospitalization among high-risk outpatients with COVID-19.
Related Publications
Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial
The Lancet Global Health • 2022
The Lancet
COVID-19
Effect of early treatment with ivermectin among patients with Covid-19
New England Journal of Medicine • 2022
COVID-19
Ivermectin
Interventions to improve adherence to antiretroviral therapy: a systematic review and network meta-analysis
The Lancet HIV • 2017
The Lancet
HIV/AIDS